With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

In this podcast, Motley Fool host Dylan Lewis and analysts Tim Beyers and Bill Mann discuss: The Fed's continued wait-and-see ...

Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ETCompany ParticipantsTara Brady - Interim CFOShantanu Gaur ...

Meanwhile, follow-up GLP-1 agonist Ozempic (semaglutide) has shown encouraging results in a phase 3 trial, and its once-weekly dosing may encourage greater take-up. Novo Nordisk applied to the FDA ...

The Colorado Sun: Colorado Mental Health Providers Say They Were “Betrayed” By Medicaid Behavioral health providers stepped up to offer new services to fill a gap, but the promise of higher ...

This translated to a loss of 22.8 kg in the tirzepatide-treated patients versus 15.0 kg in those who received semaglutide. David Horner, MD, PhD (Copenhagen University Hospital, Denmark), who wasn’t ...

MALAGA, Spain—Clinicians caring for patients with obesity or overweight and established cardiovascular disease should start patients on semaglutide (Wegovy; Novo Nordisk) as soon as possible. That’s ...

The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58 respectively) Within ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

Whereas semaglutide works by activating receptors for a hormone called glucagon-like peptide 1, or GLP-1, tirzepatide mimics not only GLP-1 but an additional hormone, glucose-dependent ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.